Arthritis Innovation Corporation   Report issue

For profit Phase 3
Founded: Toronto Canada (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2018
NCT03541655
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Arthritis Innovation Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pain, Postoperative (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4